Creso Pharma Limited
COPHF · OTC
12/31/2023 | 12/31/2022 | 12/31/2021 | 12/31/2020 | |
|---|---|---|---|---|
| Revenue | $18,921 | $8,689 | $6,218 | $2,448 |
| % Growth | 117.8% | 39.7% | 154% | – |
| Cost of Goods Sold | $16,586 | $8,402 | $6,619 | $6,330 |
| Gross Profit | $2,335 | $287 | -$401 | -$3,882 |
| % Margin | 12.3% | 3.3% | -6.4% | -158.6% |
| R&D Expenses | $0 | $0 | $0 | $345 |
| G&A Expenses | $5,264 | $6,214 | $4,350 | $3,264 |
| SG&A Expenses | $6,058 | $7,897 | $10,189 | $4,251 |
| Sales & Mktg Exp. | $794 | $1,683 | $5,839 | $986 |
| Other Operating Expenses | -$3,723 | $11,582 | $17,764 | $5,890 |
| Operating Expenses | $2,335 | $19,479 | $27,952 | $10,486 |
| Operating Income | -$16,680 | -$19,567 | -$28,325 | -$16,839 |
| % Margin | -88.2% | -225.2% | -455.5% | -687.9% |
| Other Income/Exp. Net | -$18,843 | -$13,213 | -$1,706 | -$13,940 |
| Pre-Tax Income | -$35,523 | -$32,780 | -$30,031 | -$30,780 |
| Tax Expense | -$3 | $2 | $1,735 | $6,798 |
| Net Income | -$52,446 | -$32,782 | -$31,766 | -$37,577 |
| % Margin | -277.2% | -377.3% | -510.8% | -1,535.2% |
| EPS | 0 | -0.022 | -0.029 | -0.1 |
| % Growth | 100% | 22% | 71.3% | – |
| EPS Diluted | 0 | -0.022 | -0.029 | -0.1 |
| Weighted Avg Shares Out | 0 | 1,463,482 | 1,107,289 | 370,838 |
| Weighted Avg Shares Out Dil | 0 | 1,463,482 | 1,107,289 | 370,838 |
| Supplemental Information | – | – | – | – |
| Interest Income | $679 | $84 | $0 | $0 |
| Interest Expense | $9,691 | $692 | $1,706 | $9,269 |
| Depreciation & Amortization | $675 | $1,949 | $266 | $352 |
| EBITDA | -$25,157 | -$17,618 | -$28,058 | -$16,487 |
| % Margin | -133% | -202.8% | -451.2% | -673.5% |